Real-World Hematologic and Spleen Outcomes With Pacritinib in Myelofibrosis-Associated Anemia: A Report of Two Cases (SOHO 2026) - Sep 1, 2026 - Abstract #MDS-566; " Case 1 was a 69-year-old man with JAK2 V617F–positive, Dynamic International Prognostic Scoring System (DIPSS) low-risk primary MF, a JAK2-only mutation profile, recent peripheral blasts <1%, anemia (hemoglobin [Hb] 120 g/L), platelets 120 × 109/L, white blood cells (WBCs) 6.07 × 109/L, constitutional symptoms, and ultrasound-assessed splenomegaly (28 cm) despite ruxolitinib therapy (15 mg twice daily). In these two early real-world cases, pacritinib was associated with improved or preserved Hb, stable leukocyte and platelet counts, and measurable spleen reduction in Case 1. These findings support further evaluation of pacritinib in MF-associated anemia and cytopenias."
Clinical • Real-world • Real-world evidence • Myelofibrosis • Oncology • ACVR1 • ASXL1 • IRAK1 • JAK1
|
|
Taghreed Al Essa MD PhD; Mohammad Zureiqi MD PhD; Hind Abdelaziz MD,PhD
|